18 Dec 2014 07:00
C4X Discovery renews collaboration with Evotec AG
Manchester and London, UK, 18 December, 2014 - C4X Discovery (C4XD), a leader in rational drug discovery and design, announced today that it has extended its research collaboration agreement with Evotec, under which C4XD's proprietary NMR-based technology and conformational design expertise is applied across a number of Evotec's pre-clinical therapeutic projects to enhance lead discovery and hit identification.
C4XD has the only technology in the world that can generate accurate, experimentally-derived dynamic solution 3D structures of drug molecules in just a matter of days, helping to accelerate product development. It can be used in conjunction with existing technologies for structure-based drug design and can make a particularly high impact when protein crystallography is not routinely available, as is the case for GPCRs and ion channels.
The technology can also be applied to help identify and generate novel crystal polymorph forms, with exciting potential applications in the life cycle management of existing branded pharmaceuticals.
Piers Morgan, CEO of C4X, said "We are delighted to renew and extend our partnership with Evotec, a global leader in high-quality drug discovery solutions. This collaboration has generated valuable data underpinning the advantages and benefits of C4XD's technology."
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are pleased to continue working with C4XD and are excited by the progress so far with this alliance. C4XD has a highly innovative platform technology which complements our strong research base to accelerate product development."
--ENDS--
For further information please contact:
C4X Discovery Ltd
Piers Morgan, CEO 07912 293832
Ross Andrews / Dan Bate, Zeus Capital 016 1831 1512
Dominic Wilson, Zeus Capital 020 7533 7727
Matthew Cole / Ben Atwell / Matthew Moss, FTI Consulting 020 3727 1000
comms@c4xdiscovery.com
About C4X Discovery Ltd
C4X Discovery is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4X Discovery's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4X Discovery is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates.www.c4xdiscovery.com
About Evotec
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with strategic partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com.